Stoke Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300RD25SS2DIJHJ67 - ISIN
US86150R1077 (STOK )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. Read full profile
Fundamentals
- Net revenue
€170.50M - Gross margin
98.9% - EBIT
€34.36M - EBIT margin
20.2% - Net income
€44.77M - Net margin
26.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
|
|
|
|
| Kaye Edward M. MD | N/A |
|
|
|
|
| Ticho Barry | CHIEF MEDICAL OFFICER |
|
|
|
|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
|
|
|
|
| Kaye Edward M. MD | N/A |
|
|
|
|
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |